Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $35.00 at The Goldman Sachs Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target lifted by The Goldman Sachs Group from $31.00 to $35.00 in a report published on Friday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other analysts have also issued reports on the stock. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target on the stock. Scotiabank initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price for the company. UBS Group lifted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 13th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $31.63.

Teva Pharmaceutical Industries Trading Up 0.2%

TEVA opened at $30.39 on Friday. The stock has a market capitalization of $34.86 billion, a price-to-earnings ratio of 50.65, a P/E/G ratio of 1.81 and a beta of 0.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $30.56. The company has a 50-day simple moving average of $24.44 and a 200 day simple moving average of $20.04.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the sale, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 622,060 shares of company stock valued at $17,076,965. Company insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares during the last quarter. Menora Mivtachim Holdings LTD. lifted its holdings in Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares during the period. Phoenix Financial Ltd. lifted its holdings in Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after buying an additional 9,094,372 shares during the period. Soundwatch Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $143,533,000. Finally, Wellington Management Group LLP grew its position in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after buying an additional 6,878,304 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Goldman Sachs raised its price target on TEVA to $35 and reiterated a “buy” rating, signaling Wall Street conviction in upside versus the current level. Goldman Sachs price target raise
• Positive Sentiment: Additional analyst support: JPMorgan, BofA and Barclays have recently increased targets/ratings (JPMorgan to $35, BofA to $32, Barclays initiating overweight), which likely helped lift sentiment and buying interest. Analyst notes
• Positive Sentiment: Teva’s U.S. affiliate and Alvotech reached a settlement and license with Regeneron setting a U.S. launch window for AVT06 (a proposed biosimilar to Eylea) in Q4 2026 (or earlier under certain conditions) — this reduces launch uncertainty and creates a clearer commercialization timeline. Alvotech settlement
• Neutral Sentiment: Institutional activity is mixed but notable: several funds increased stakes (e.g., Hudson Bay Capital bought more), supporting the view that institutions are accumulating at current levels. Institutional trading
• Neutral Sentiment: Coverage pieces from Zacks and The Motley Fool highlight TEVA as a value/long-term holding — these narrative articles may attract retail interest but are less likely to move price materially on their own. Zacks coverage
• Negative Sentiment: Insider selling: CAO Amir Weiss sold 12,300 shares and Director Roberto Mignone sold 77,400 shares in mid-December at ~\$30.20–30.24 — sizable disclosed sales that may concern some investors about near-term insider conviction. Insider sales

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.